Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis? - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Does Kaposi’s sarcoma signal the conclusion of the OX40/OX40L pathway in atopic dermatitis treatment?

  • By

  • Shahram Salek-Ardakani

  • June 2, 2026

Share

  • 1

    The OX40/OX40L axis showed initial promise in treating atopic dermatitis but faced challenges due to safety concerns linked to Kaposi’s sarcoma.

  • 2

    Rocatinlimab and amlitelimab trials were halted after confirmed cases of Kaposi’s sarcoma, raising questions about the safety of OX40/OX40L modulation.

  • 3

    Despite safety concerns, the biological rationale for targeting the OX40/OX40L pathway in atopic dermatitis remains compelling and warrants further investigation.

  • 4

    The treatment landscape for atopic dermatitis is evolving, necessitating new therapies to demonstrate significant benefits over existing options.

  • 5

    Future development strategies for OX40/OX40L targeting must balance therapeutic benefits with the risks of immune surveillance disruption.

Original Source(s)

Is Kaposi’s sarcoma the end of the OX40/OX40L axis in atopic dermatitis?

  • by Shahram Salek-Ardakani

  • June 2, 2026

Related Content

The Role of Inflammatory Biomarkers in Disease Severity and Treatment Response across Psoriasis, Atopic Dermatitis, and Hidradenitis Suppurativa—A Narrative Review

Informatics-Based Psychotherapeutic and Psychiatric Interventions in Dermatology: Scoping Review of Impacts on Skin Disease Severity and Mental Health Outcomes

Daily Itch Duration Linked to Quality-of-Life Burden

Daily itch duration emerged as the strongest factor linking disease severity with quality of life, ahead of sleep disturbance, scratching frequency, and average itch intensity.